Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease

Chagas Cardiomyopathy—Where Do We Stand After a Hundred Years?

(2010) Andréia Biolo et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction

(2009) Jamille Fernandes Lula et al.   EUROPEAN JOURNAL OF HEART FAILURE

Immunological imbalance between IFN-³ and IL-10 levels in the sera of patients with the cardiac form of Chagas disease

(2009) Daniela A D'Ávila et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Ergosterol biosynthesis and drug development for Chagas disease

(2009) Julio A Urbina   MEMORIAS DO INSTITUTO OSWALDO CRUZ

The role of parasite persistence in pathogenesis of Chagas heart disease

(2009) F. R. S. GUTIERREZ et al.   PARASITE IMMUNOLOGY

Perspectives on Trypanosoma cruzi–Induced Heart Disease (Chagas Disease)

(2009) Herbert B. Tanowitz et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-γ, TNF-α, and low IL-10 production during the acute infection phase

(2009) Paulo M.M. Guedes et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes

(2008) H. R. Martins et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions

(2008) Ivo Santana Caldas et al.   PARASITOLOGY RESEARCH